Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NBI-1070770 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| NBI-1070770: Low Dose | EXPERIMENTAL | Participants will receive low-dose NBI-1070770. |
| NBI-1070770: Medium Dose | EXPERIMENTAL | Participants will receive medium-dose NBI-1070770. |
| NBI-1070770: High Dose | EXPERIMENTAL | Participants will receive high-dose NBI-1070770. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo. |
| Name | Type | Description |
|---|---|---|
| NBI-1070770 | DRUG | Suspension for oral administration |
| Placebo | DRUG | Suspension for oral administration |
Key Inclusion Criteria: Participants must meet all of the following inclusion criteria: * Primary diagnosis of recurrent MDD or persistent MDD. * Participants currently receiving pharmacological treatment for depression must have been taking current antidepressant medication(s) for ≥8 weeks prior ...
Top 20 of 31 competitors
NBI-1070770 is an investigational small molecule being developed by Neurocrine Biosciences for the treatment of major depressive disorder. It is a GPR139-targeted compound and has been studied in a Phase 2 clinical trial. It is not approved for any indication and remains in clinical development.
NBI-1070770 is being evaluated for the treatment of major depressive disorder in adults. It is an investigational therapy and has not been approved for any use. The clinical program has focused on adults aged 18 years and older with a diagnosis of major depressive disorder.
NBI-1070770 targets GPR139, an orphan G protein-coupled receptor. By interacting with this receptor, the drug is designed to modulate a specific signaling pathway relevant to major depressive disorder. GPR139 is the molecular target of the compound.
NBI-1070770 is being developed by Neurocrine Biosciences, Inc., which trades on the Nasdaq under the ticker NBIX. The company is the sponsor of the clinical program evaluating the drug in major depressive disorder.
NBI-1070770 is in Phase 2 clinical development. A Phase 2 trial in adults with major depressive disorder has been completed. The drug is investigational and has not been approved by the FDA or any regulatory authority for any indication.
NBI-1070770 has been studied in one Phase 2 clinical trial, NCT06267846, titled A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder. The trial was completed, enrolled 73 participants, and was randomized, double-blind, and placebo-controlled, conducted in the United States.